Heterozygous Alterations of TNFRSF13B/TACI in Tonsillar Hypertrophy and Sarcoidosis

Table 1

Clinical and demographic characteristics of the patients of the study.

Patients with sarcoidosis
No	71
Sex (male/female)	24/47
Age (mean, range)	49.9, 20–74
Clinical characteristics
Löfgren’s syndrome (𝑛, %)	12, 16.9
Ocular involvement (𝑛, %)	4, 5,6
Skin involvement (𝑛, %)	17, 23.9
Peripheral lymphadenopathy (𝑛, %)	3, 4.3
Autoimmune manifestations*	15, 21.1
Chest X-Ray (CXR) staging
(0) Without mediastinum and lung involvement (𝑛, %)	2, 2.8
(I) Mediastinal adenopathy (𝑛, %)	13, 18.3
(II) Mediastinal adenopathy + lung involvement (𝑛, %)	54, 76.1
(III) Lung involvement only (𝑛, %)	2, 2.8
(IV) Lung fibrosis (𝑛, %)	0
Corticosteroid treatment (𝑛, %)^#	45, 63.4
Patients with tonsillar hypertrophy without infectious causative
No	19
Sex (male/female)	11/8
Age (mean, range)	12.1, 3–40
Patients with tonsillar hypertrophy due to H. influenzae
No	15
Sex (male/female)	6/9
Age (mean, range)	10.1, 3–59

∗Autoimmune manifestations include the presence of Hashimoto thyroiditis, rheumatoid arthritis, or Sjögren syndrome.
#Corticosteroid treatment refers to patients who received either per os or inhaled corticosteroids during the follow-up period.